Interplay between Kitaev interaction and single ion anisotropy in ferromagnetic CrI3_3 and CrGeTe3_3 monolayers

Magnetic anisotropy is crucially important for the stabilization of two-dimensional (2D) magnetism, which is rare in nature but highly desirable in spintronics and for advancing fundamental knowledge. Recent works on CrI$_3$ and CrGeTe$_3$ monolayers not only led to observations of the long-time-sought 2D ferromagnetism, but also revealed distinct magnetic anisotropy in the two systems, namely Ising behavior for CrI$_3$ versus Heisenberg behavior for CrGeTe$_3$. Such magnetic difference strongly contrasts with structural and electronic similarities of these two materials, and understanding it at a microscopic scale should be of large benefits. Here, first-principles calculations are performed and analyzed to develop a simple Hamiltonian, to investigate magnetic anisotropy of CrI$_3$ and CrGeTe$_3$ monolayers. The anisotropic exchange coupling in both systems is surprisingly determined to be of Kitaev-type. Moreover, the interplay between this Kitaev interaction and single ion anisotropy (SIA) is found to naturally explain the different magnetic behaviors of CrI$_3$ and CrGeTe$_3$. Finally, both the Kitaev interaction and SIA are further found to be induced by spin-orbit coupling of the heavy ligands (I of CrI$_3$ or Te of CrGeTe$_3$) rather than the commonly believed 3d magnetic Cr ions

Rolling element bearing fault diagnosis using laplace-wavelet envelope power spectrum

The bearing characteristic frequencies (BCF) contain very little energy, and are usually overwhelmed by noise and higher levels of macro-structural vibrations. They are difficult to find in their frequency spectra when using the common technique of fast fourier transforms (FFT). Therefore, Envelope Detection (ED) has always been used with FFT to identify faults occurring at the BCF. However, the computation of the ED is suffering to strictly define the resonance frequency band. In this paper, an alternative approach based on the Laplace-wavelet enveloped power spectrum is proposed. The Laplace-Wavelet shape parameters are optimized based on Kurtosis maximization criteria. The results for simulated as well as real bearing vibration signal show the effectiveness of the proposed method to extract the bearing fault characteristic frequencies from the resonant frequency band.Khalid F. Al-Raheem, Asok Roy, K. P. Ramachandran, D. K. Harrison, and Steven Grainge

EGCG Enhances the Therapeutic Potential of Gemcitabine and CP690550 by Inhibiting STAT3 Signaling Pathway in Human Pancreatic Cancer

Background: Signal Transducer and Activator of Transcription 3 (STAT3) is an oncogene, which promotes cell survival, proliferation, motility and progression in cancer cells. Targeting STAT3 signaling may lead to the development of novel therapeutic approaches for human cancers. Here, we examined the effects of epigallocathechin gallate (EGCG) on STAT3 signaling in pancreatic cancer cells, and assessed the therapeutic potential of EGCG with gemcitabine or JAK3 inhibitor CP690550 (Tasocitinib) for the treatment and/or prevention of pancreatic cancer. Methodology/Principal Findings: Cell viability and apoptosis were measured by XTT assay and TUNEL staining, respectively. Gene and protein expressions were measured by qRT-PCR and Western blot analysis, respectively. The results revealed that EGCG inhibited the expression of phospho and total JAK3 and STAT3, STAT3 transcription and activation, and the expression of STAT3-regulated genes, resulting in the inhibition of cell motility, migration and invasion, and the induction of caspase-3 and PARP cleavage. The inhibition of STAT3 enhanced the inhibitory effects of EGCG on cell motility and viability. Additionally, gemcitabine and CP690550 alone inhibited STAT3 target genes and synergized with EGCG to inhibit cell viability and induce apoptosis in pancreatic cancer cells. Conclusions/Significance: Overall, these results suggest that EGCG suppresses the growth, invasion and migration of pancreatic cancer cells, and induces apoptosis by interfering with the STAT3 signaling pathway. Moreover, EGCG furthe

Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion

The effects of the glycoprotein IIb/IIIa receptor inhibitor tirofiban in patients with acute ischemic stroke but who have no evidence of complete occlusion of large or medium-sized vessels have not been extensively studied. In a multicenter trial in China, we enrolled patients with ischemic stroke without occlusion of large or medium-sized vessels and with a National Institutes of Health Stroke Scale score of 5 or more and at least one moderately to severely weak limb. Eligible patients had any of four clinical presentations: ineligible for thrombolysis or thrombectomy and within 24 hours after the patient was last known to be well; progression of stroke symptoms 24 to 96 hours after onset; early neurologic deterioration after thrombolysis; or thrombolysis with no improvement at 4 to 24 hours. Patients were assigned to receive intravenous tirofiban (plus oral placebo) or oral aspirin (100 mg per day, plus intravenous placebo) for 2 days; all patients then received oral aspirin until day 90. The primary efficacy end point was an excellent outcome, defined as a score of 0 or 1 on the modified Rankin scale (range, 0 [no symptoms] to 6 [death]) at 90 days. Secondary end points included functional independence at 90 days and a quality-of-life score. The primary safety end points were death and symptomatic intracranial hemorrhage. A total of 606 patients were assigned to the tirofiban group and 571 to the aspirin group. Most patients had small infarctions that were presumed to be atherosclerotic. The percentage of patients with a score of 0 or 1 on the modified Rankin scale at 90 days was 29.1% with tirofiban and 22.2% with aspirin (adjusted risk ratio, 1.26; 95% confidence interval, 1.04 to 1.53, P = 0.02). Results for secondary end points were generally not consistent with the results of the primary analysis. Mortality was similar in the two groups. The incidence of symptomatic intracranial hemorrhage was 1.0% in the tirofiban group and 0% in the aspirin group. In this trial involving heterogeneous groups of patients with stroke of recent onset or progression of stroke symptoms and nonoccluded large and medium-sized cerebral vessels, intravenous tirofiban was associated with a greater likelihood of an excellent outcome than low-dose aspirin. Incidences of intracranial hemorrhages were low but slightly higher with tirofiban

Methylprednisolone as Adjunct to Endovascular Thrombectomy for Large-Vessel Occlusion Stroke

Importance It is uncertain whether intravenous methylprednisolone improves outcomes for patients with acute ischemic stroke due to large-vessel occlusion (LVO) undergoing endovascular thrombectomy. Objective To assess the efficacy and adverse events of adjunctive intravenous low-dose methylprednisolone to endovascular thrombectomy for acute ischemic stroke secondary to LVO. Design, Setting, and Participants This investigator-initiated, randomized, double-blind, placebo-controlled trial was implemented at 82 hospitals in China, enrolling 1680 patients with stroke and proximal intracranial LVO presenting within 24 hours of time last known to be well. Recruitment took place between February 9, 2022, and June 30, 2023, with a final follow-up on September 30, 2023.InterventionsEligible patients were randomly assigned to intravenous methylprednisolone (n = 839) at 2 mg/kg/d or placebo (n = 841) for 3 days adjunctive to endovascular thrombectomy. Main Outcomes and Measures The primary efficacy outcome was disability level at 90 days as measured by the overall distribution of the modified Rankin Scale scores (range, 0 [no symptoms] to 6 [death]). The primary safety outcomes included mortality at 90 days and the incidence of symptomatic intracranial hemorrhage within 48 hours. Results Among 1680 patients randomized (median age, 69 years; 727 female [43.3%]), 1673 (99.6%) completed the trial. The median 90-day modified Rankin Scale score was 3 (IQR, 1-5) in the methylprednisolone group vs 3 (IQR, 1-6) in the placebo group (adjusted generalized odds ratio for a lower level of disability, 1.10 [95% CI, 0.96-1.25]; P = .17). In the methylprednisolone group, there was a lower mortality rate (23.2% vs 28.5%; adjusted risk ratio, 0.84 [95% CI, 0.71-0.98]; P = .03) and a lower rate of symptomatic intracranial hemorrhage (8.6% vs 11.7%; adjusted risk ratio, 0.74 [95% CI, 0.55-0.99]; P = .04) compared with placebo. Conclusions and Relevance Among patients with acute ischemic stroke due to LVO undergoing endovascular thrombectomy, adjunctive methylprednisolone added to endovascular thrombectomy did not significantly improve the degree of overall disability.Trial RegistrationChiCTR.org.cn Identifier: ChiCTR210005172

The Cost and Benefit of Fear Induction Parenting on Children’s Health during the COVID-19 Outbreak

Objective. The outbreak of the 2019 coronavirus disease (COVID-19) was an unprecedented global public health emergency with a significant psychological toll. This study aimed to understand how specific COVID-19 related stressors contributed to Chinese parents’ fear induction practices, and how these practices, in turn, contributed to their children’s disease prevention practices during the outbreak and depressive symptoms after the outbreak. Method. Parents (N=240, Mage=38.50 years, 75% mothers) with elementary-school-aged children (Mage=9.48 years, 46% girls) in Wenzhou, one of the most impacted cities in China, reported on the presence of confirmed or suspected cases in their communities, their frequencies of consuming COVID-19-related information, fear induction practices, and their children’s trait anxiety and disease prevention practices during the outbreak (January 28 to 30, 2020). Child-reported depressive symptoms were collected between March 7 and 11, 2020, during which there were very few remaining cases and no new confirmed cases or deaths. Results. Parents’ higher frequency of virus-related information consumption but not the presence of community infection was associated with their engagement in more fear induction practices, which was in turn associated with children’s greater engagement in prevention practices during the outbreak, but more post-quarantine depressive symptoms. Child trait anxiety exacerbated the association between parent fear induction and child depressive symptoms. Conclusion. Using fear induction parenting may promote children’s willingness to cooperate and participate in disease prevention practices during the crisis but at the cost of children’s long-term mental health